Patrick Yeramian
Corporate Officer/Principal at Dlx Therapeutics L L C
Net worth: 583 918 $ as of 2024-03-30
Profile
Patrick D.
Yeramian is currently the General Manager at Dlx Therapeutics L L C.
Previously, he worked as a Medical Director at Pfizer Inc., Marker Therapeutics, Inc., Vaccine & Gene Therapy Institute of Florida Corp., Kantum Pharma, Inc., and Tapimmune, Inc. He also served as the Director-Clinical Research at G.D.
Searle LLC and as the Chief Medical Officer at Viragen, Inc. and BioVie, Inc. Additionally, he is currently the Chief Medical Officer & Global Head-Clinical R&D at Amylyx Pharmaceuticals, Inc. Dr. Yeramian holds a graduate degree from Université de Paris XI Paris Sud, a doctorate from Universite Paris Est.
Creteil Val De Marne, and an MBA from Rutgers Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-08 | 205,605 ( 0.30% ) | 583 918 $ | 2024-03-30 |
Patrick Yeramian active positions
| Companies | Position | Start |
|---|---|---|
| Dlx Therapeutics L L C | Corporate Officer/Principal | 2017-12-31 |
Former positions of Patrick Yeramian
| Companies | Position | End |
|---|---|---|
| AMYLYX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2023-11-27 |
| BIOVIE INC. | Chief Tech/Sci/R&D Officer | 2021-10-31 |
Kantum Pharma, Inc.
 Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Chief Tech/Sci/R&D Officer | 2019-02-28 |
| MARKER THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2016-12-31 |
| Tapimmune, Inc. | Chief Tech/Sci/R&D Officer | 2016-12-31 |
Training of Patrick Yeramian
| Universite Paris Est Creteil Val De Marne | Doctorate Degree |
| Rutgers Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| MARKER THERAPEUTICS, INC. | Health Technology |
| BIOVIE INC. | Health Technology |
| AMYLYX PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL. | Health Technology |
| Université de Paris XI Paris Sud | Consumer Services |
| G.D. Searle LLC | |
Vaccine & Gene Therapy Institute of Florida Corp.
 Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Vaccine & Gene Therapy Institute of Florida Corp. provides research services. The non-profit company is based in Port Saint Lucie, FL. | Commercial Services |
Kantum Pharma, Inc.
Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Commercial Services |
| Dlx Therapeutics L L C | |
| Tapimmune, Inc. |
- Stock Market
- Insiders
- Patrick Yeramian
